Romiplostim Dosing for Immune Thrombocytopenia
For adults with ITP, start romiplostim at 1 mcg/kg subcutaneously weekly, titrating by 1 mcg/kg increments to maintain platelets ≥50×10⁹/L (maximum 10 mcg/kg weekly); for pediatric patients ≥1 year old, use the same starting dose of 1 mcg/kg weekly with identical titration strategy, but reassess body weight every 12 weeks for dose recalculation 1.
Adult Dosing Algorithm
Initial dose: 1 mcg/kg subcutaneously once weekly, calculated using actual body weight 1.
Dose adjustments (weekly increments of 1 mcg/kg):
- Platelet count <50×10⁹/L: Increase dose by 1 mcg/kg
- Platelet count 200-400×10⁹/L for 2 consecutive weeks: Reduce dose by 1 mcg/kg
- Platelet count >400×10⁹/L: Hold dose, monitor weekly; resume at 1 mcg/kg lower when platelets fall below 200×10⁹/L 1
Maximum dose: 10 mcg/kg weekly. Discontinue if no adequate response after 4 weeks at maximum dose 1.
Target maintenance: Most adults achieve platelet counts ≥50×10⁹/L at median doses of 2-3 mcg/kg weekly 1.
Pediatric Dosing Algorithm (≥1 Year Old)
Initial dose: 1 mcg/kg subcutaneously once weekly, calculated using actual body weight 1.
Critical difference from adults: Reassess body weight every 12 weeks and recalculate dose accordingly, as pediatric dose adjustments depend on both platelet response AND weight changes 1.
Dose adjustments (identical platelet-based algorithm as adults):
- Platelet count <50×10⁹/L: Increase by 1 mcg/kg
- Platelet count 200-400×10⁹/L for 2 consecutive weeks: Reduce by 1 mcg/kg
- Platelet count >400×10⁹/L: Hold dose, monitor weekly; resume at 1 mcg/kg lower when <200×10⁹/L 1
Maximum dose: 10 mcg/kg weekly 1.
Expected maintenance: In pediatric trials, the median most frequent dose during weeks 17-24 was 5.5 mcg/kg, notably higher than adult maintenance doses 1.
Monitoring Requirements
During dose titration: Weekly complete blood counts with platelet counts 1.
After stable dose achieved: Monthly complete blood counts 1.
After discontinuation: Weekly platelet counts for at least 2 weeks 1.
Administration Considerations
Route: Subcutaneous injection only—never administer intravenously 1.
Syringe requirement: Use only syringes with 0.01 mL graduations, as prescribed doses may be very small volumes (e.g., 0.15 mL) 1.
Reconstitution: Use only Sterile Water for Injection; never use Bacteriostatic Water for Injection or Bacteriostatic Sodium Chloride 1.
Dilution for low doses: If calculated patient dose is <23 mcg, dilute with 0.9% Sodium Chloride to achieve 125 mcg/mL concentration for accurate measurement 1.
Clinical Context from Guidelines
The 2019 and 2024 ASH guidelines recommend TPO-RAs (including romiplostim) over rituximab for adults with persistent/chronic ITP (≥3 months duration) who are corticosteroid-dependent or non-responsive 2, 3. For pediatric patients with non-life-threatening mucosal bleeding or diminished quality of life who fail first-line treatment, TPO-RAs are recommended options 2, 3.
Common Pitfalls to Avoid
Do not use higher initial doses routinely: While research suggests higher initial doses (≥3 mcg/kg) may accelerate platelet response in hospitalized, refractory patients 4, 5, the FDA-approved starting dose remains 1 mcg/kg for both adults and children. Higher initial dosing lacks sufficient safety data for routine use 1.
Do not forget weight-based recalculation in children: Unlike adults where future adjustments are platelet-based only, pediatric patients require weight reassessment every 12 weeks with dose recalculation 1.
Do not continue indefinitely without response: Discontinue after 4 weeks at maximum dose (10 mcg/kg) if platelets remain insufficient to prevent clinically important bleeding 1.
Do not use wrong diluent: Bacteriostatic products will compromise drug stability and efficacy 1.
Acute Radiation Syndrome Dosing (Distinct Indication)
For myelosuppressive radiation exposure (>2 Gray): Single dose of 10 mcg/kg subcutaneously as soon as possible after exposure, regardless of whether CBC can be obtained 1. This is a completely different dosing paradigm from ITP management.